SATB2, a marker highly sensitive to osteoblastic differentiation, is primarily observed in both benign and malignant bone tumors with osteoblastic features, as well as in soft tissue tumors exhibiting heterogeneous bone differentiation (16). The gene discussed is SATB2; the disease is soft tissue neoplasm.